Tesaro Archives -

News/ News/ R&D/ Top stories

GSK enters PARP space with TESARO acquisition

George Underwood GSK, PARP, Tesaro 0 Comment

GSK has announced that it will acquire US-based oncology specialist TESARO for $5.1 billion, gaining access to its

GSK enters PARP space with TESARO acquisition

https://pharmaphorum.com/news/gsk-enters-parp-space-with-tesaro-acquisition/

News/ News/ Oncology/ R&D/ Roche/ Top pharmaceutical companies

Tesaro stock rockets as rumours of Roche takeover abound

Joy Persaud cancer, Clovis Oncology, Oncology, Roche, Rubraca, Tesaro, Zejula 0 Comment

Shares in US biotech Tesaro peaked this week amid speculation that Roche is making plans to buy it.

Tesaro stock rockets as rumours of Roche takeover abound

https://pharmaphorum.com/news/tesaro-stock-rockets-roche-takeover-abound/

ASCO 2018/ Event coverage/ Oncology/ Views & Analysis/ Views and analysis

ASCO 2018 – Tuesday 5th June: Tesaro developing checkpoint combo

Richard Staines ASCO 2018, breast cancer, cancer, Loxo, ovarian cancer, Tesaro 0 Comment

Breast cancer has been one area where checkpoint inhibitors have not yet gained traction – but that might

ASCO 2018 – Tuesday 5th June: Tesaro developing checkpoint combo

https://pharmaphorum.com/views-and-analysis/asco-2018-tesaro-checkpoint-combo/

News/ News/ Oncology

Clovis’ PARP drug gets new US ovarian cancer use

Richard Staines AstraZeneca, cancer, Clovis Oncology, ovarian cancer, Tesaro 0 Comment

Rucaparib gets FDA OK in maintenance use

Clovis’ PARP drug gets new US ovarian cancer use

https://pharmaphorum.com/news/clovis-parp-drug-gets-new-us-ovarian-cancer-use/

News/ Oncology/ UK & Europe

Clovis’ Rubraca close to EU approval in ovarian cancer

Richard Staines AstraZeneca, cancer, Clovis Oncology, ovarian cancer, Tesaro 0 Comment

CHMP backs conditional approval for PARP drug

Clovis’ Rubraca close to EU approval in ovarian cancer

https://pharmaphorum.com/oncology/clovis-rubraca-close-eu-approval-ovarian-cancer/

Market Access/ News/ News/ News/ News/ News/ Oncology/ R&D/ Sales and Marketing

Tesaro and Roche to combine drugs in bladder cancer trials

Andrew McConaghie AstraZeneca, Lynparza, PARP inhibitors, Tesaro 0 Comment

Tesaro is to combine its PARP-inhibitor drug Zejula with Roche’s PD-L1 immunotherapy Tecentriq in clinical trials for metastatic bladder cancer.

Tesaro and Roche to combine drugs in bladder cancer trials

https://pharmaphorum.com/news/tesaro-roche-combine-drugs-bladder-cancer-trials/

Cancer/ News/ News/ News/ Oncology/ R&D/ US

AZ’s Lynparza becomes first PARP drug approved in breast cancer

Richard Staines AstraZeneca, breast cancer, cancer, Clovis, ovarian cancer, Tesaro 0 Comment

Lynparza first in class approved in breast cancer

AZ’s Lynparza becomes first PARP drug approved in breast cancer

https://pharmaphorum.com/news/azs-lynparza-becomes-first-approved-parp-drug-breast-cancer/

News/ News/ Oncology/ US

Clovis PARP drug gets fast US review in new ovarian cancer use

Richard Staines AstraZeneca, cancer, Clovis, Merck & Co, ovarian cancer, Tesaro 0 Comment

Impressed by survival data, FDA hastens review in expanded patient group

Clovis PARP drug gets fast US review in new ovarian cancer use

https://pharmaphorum.com/news/clovis-rubruca-fast-review/

News/ News/ Oncology/ UK & Europe

Tesaro gets European approval on Zejula, set to challenge AZ

Richard Staines AstraZeneca, cancer, ovarian cancer, Tesaro 0 Comment

Tesaro’s PARP drug approved in wider ovarian cancer population

Tesaro gets European approval on Zejula, set to challenge AZ

https://pharmaphorum.com/news/az-ovarian-cancer-drug-facing-eu-competition-tesaro/

Trending

Tesaro

Login